top of page

Dr. Chandler Walker moves to final round of IU Idea to Startup Pitch Competition

Dr. Walkers business idea "Cell-based therapy for ALS" was selected for advancing to the IU Idea to Startup Pitch Competition finals. This is an in-person event held on October 13 in Bloomington, Indiana. The winner will receive money for further establishing the startup and resources for helping move the idea forward in clinical production.

NDR congratulates Chandler on the opportunity to discuss Secretome as an ALS treatment in Bloomington and hope his hard work brings him the award. NDR supported his idea and funded important pre-clinical data studies bringing him to this research juncture. We hope he can continue his work to bring a promising therapy to ALS patients in a clinical trial through his company Mesocyte Therapeutics LLC.

14 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


Commenting has been turned off.
bottom of page